vs

Side-by-side financial comparison of Pulmonx Corp (LUNG) and FiscalNote Holdings, Inc. (NOTE). Click either name above to swap in a different company.

FiscalNote Holdings, Inc. is the larger business by last-quarter revenue ($22.2M vs $20.6M, roughly 1.1× Pulmonx Corp). On growth, Pulmonx Corp posted the faster year-over-year revenue change (-8.7% vs -24.7%). Over the past eight quarters, Pulmonx Corp's revenue compounded faster (-0.5% CAGR vs -16.8%).

Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.

FiscalNote Holdings, Inc., or commonly FiscalNote, is a publicly traded software, data, and media company headquartered in Washington, D.C. The company was founded by Timothy Hwang, Gerald Yao, and Jonathan Chen in 2013. FiscalNote provides software tools, platforms, data services, and news through the FiscalNote Government Relationship Management (GRM) service, its core product. The company also uses an artificial intelligence platform to analyze proposed U.S. legislation based on key phrase...

LUNG vs NOTE — Head-to-Head

Bigger by revenue
NOTE
NOTE
1.1× larger
NOTE
$22.2M
$20.6M
LUNG
Growing faster (revenue YoY)
LUNG
LUNG
+16.0% gap
LUNG
-8.7%
-24.7%
NOTE
Faster 2-yr revenue CAGR
LUNG
LUNG
Annualised
LUNG
-0.5%
-16.8%
NOTE

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
LUNG
LUNG
NOTE
NOTE
Revenue
$20.6M
$22.2M
Net Profit
$-13.7M
Gross Margin
77.9%
Operating Margin
-40.9%
-83.7%
Net Margin
-66.3%
Revenue YoY
-8.7%
-24.7%
Net Profit YoY
5.5%
EPS (diluted)
$-0.33
$-2.81

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LUNG
LUNG
NOTE
NOTE
Q1 26
$20.6M
Q4 25
$22.6M
$22.2M
Q3 25
$21.5M
$22.4M
Q2 25
$23.9M
$23.3M
Q1 25
$22.5M
$27.5M
Q4 24
$23.8M
$29.5M
Q3 24
$20.4M
$29.4M
Q2 24
$20.8M
$29.2M
Net Profit
LUNG
LUNG
NOTE
NOTE
Q1 26
$-13.7M
Q4 25
$-10.4M
Q3 25
$-14.0M
$-24.9M
Q2 25
$-15.2M
$-13.3M
Q1 25
$-14.4M
$-4.3M
Q4 24
$-13.2M
Q3 24
$-14.1M
$-14.9M
Q2 24
$-15.3M
$-12.8M
Gross Margin
LUNG
LUNG
NOTE
NOTE
Q1 26
77.9%
Q4 25
77.6%
Q3 25
74.7%
Q2 25
72.1%
Q1 25
72.5%
Q4 24
74.0%
Q3 24
73.7%
Q2 24
73.7%
Operating Margin
LUNG
LUNG
NOTE
NOTE
Q1 26
-40.9%
Q4 25
-43.8%
-83.7%
Q3 25
-66.9%
-43.4%
Q2 25
-62.0%
-31.9%
Q1 25
-64.6%
-50.0%
Q4 24
-56.5%
-19.4%
Q3 24
-69.3%
-23.1%
Q2 24
-75.2%
-27.2%
Net Margin
LUNG
LUNG
NOTE
NOTE
Q1 26
-66.3%
Q4 25
-46.1%
Q3 25
-64.9%
-110.8%
Q2 25
-63.6%
-57.0%
Q1 25
-64.1%
-15.4%
Q4 24
-55.4%
Q3 24
-69.4%
-50.7%
Q2 24
-73.7%
-43.6%
EPS (diluted)
LUNG
LUNG
NOTE
NOTE
Q1 26
$-0.33
Q4 25
$-0.25
$-2.81
Q3 25
$-0.34
$-1.73
Q2 25
$-0.38
$-0.08
Q1 25
$-0.36
$-0.03
Q4 24
$-0.33
$1.88
Q3 24
$-0.36
$-1.33
Q2 24
$-0.39
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LUNG
LUNG
NOTE
NOTE
Cash + ST InvestmentsLiquidity on hand
$61.6M
$26.3M
Total DebtLower is stronger
$37.3M
$128.4M
Stockholders' EquityBook value
$45.8M
$62.0M
Total Assets
$120.0M
$255.1M
Debt / EquityLower = less leverage
0.82×
2.07×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LUNG
LUNG
NOTE
NOTE
Q1 26
$61.6M
Q4 25
$69.8M
$26.3M
Q3 25
$76.5M
$31.2M
Q2 25
$75.5M
$38.5M
Q1 25
$74.6M
$46.3M
Q4 24
$70.9M
$34.6M
Q3 24
$63.3M
$32.7M
Q2 24
$63.5M
$37.7M
Total Debt
LUNG
LUNG
NOTE
NOTE
Q1 26
$37.3M
Q4 25
$37.1M
$128.4M
Q3 25
$37.1M
$131.5M
Q2 25
$37.1M
$116.7M
Q1 25
$37.2M
$118.0M
Q4 24
$37.2M
$147.1M
Q3 24
$37.2M
$152.2M
Q2 24
$37.2M
$145.9M
Stockholders' Equity
LUNG
LUNG
NOTE
NOTE
Q1 26
$45.8M
Q4 25
$54.1M
$62.0M
Q3 25
$60.0M
$75.5M
Q2 25
$69.1M
$95.1M
Q1 25
$77.7M
$98.7M
Q4 24
$85.8M
$97.8M
Q3 24
$93.9M
$98.5M
Q2 24
$101.2M
$106.9M
Total Assets
LUNG
LUNG
NOTE
NOTE
Q1 26
$120.0M
Q4 25
$129.3M
$255.1M
Q3 25
$138.3M
$273.9M
Q2 25
$147.2M
$288.3M
Q1 25
$150.7M
$299.7M
Q4 24
$162.8M
$326.2M
Q3 24
$167.4M
$337.9M
Q2 24
$172.6M
$346.3M
Debt / Equity
LUNG
LUNG
NOTE
NOTE
Q1 26
0.82×
Q4 25
0.69×
2.07×
Q3 25
0.62×
1.74×
Q2 25
0.54×
1.23×
Q1 25
0.48×
1.20×
Q4 24
0.43×
1.50×
Q3 24
0.40×
1.54×
Q2 24
0.37×
1.36×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LUNG
LUNG
NOTE
NOTE
Operating Cash FlowLast quarter
$-279.0K
Free Cash FlowOCF − Capex
$-1.9M
FCF MarginFCF / Revenue
-8.7%
Capex IntensityCapex / Revenue
7.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-18.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LUNG
LUNG
NOTE
NOTE
Q1 26
Q4 25
$-7.1M
$-279.0K
Q3 25
$-8.2M
$-8.3M
Q2 25
$-3.9M
$-6.2M
Q1 25
$-13.2M
$3.3M
Q4 24
$-6.7M
$-1.3M
Q3 24
$-7.2M
$-3.0M
Q2 24
$-5.8M
$-3.7M
Free Cash Flow
LUNG
LUNG
NOTE
NOTE
Q1 26
Q4 25
$-7.1M
$-1.9M
Q3 25
$-8.3M
$-10.4M
Q2 25
$-4.0M
$-7.7M
Q1 25
$-13.5M
$1.3M
Q4 24
$-6.8M
$-3.4M
Q3 24
$-7.7M
$-5.4M
Q2 24
$-6.2M
$-6.5M
FCF Margin
LUNG
LUNG
NOTE
NOTE
Q1 26
Q4 25
-31.4%
-8.7%
Q3 25
-38.4%
-46.2%
Q2 25
-16.6%
-33.0%
Q1 25
-60.0%
4.7%
Q4 24
-28.8%
-11.4%
Q3 24
-37.6%
-18.4%
Q2 24
-30.0%
-22.1%
Capex Intensity
LUNG
LUNG
NOTE
NOTE
Q1 26
Q4 25
0.1%
7.4%
Q3 25
0.4%
9.3%
Q2 25
0.2%
6.4%
Q1 25
1.3%
7.2%
Q4 24
0.5%
6.8%
Q3 24
2.0%
8.3%
Q2 24
2.3%
9.4%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LUNG
LUNG

Segment breakdown not available.

NOTE
NOTE

Subscription$21.2M95%
Advisory Advertising And Other$1.0M5%

Related Comparisons